Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.64 |
| ▸ | DRD5 | P21918 | 8/20 | 0.64 |
| ▸ | DRD2 | P14416 | 8/20 | 0.64 |
| ▸ | DRD3 | P35462 | 8/20 | 0.64 |
| ▸ | DRD4 | P21917 | 5/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13068804 | 0.89 | DRD1 (0.56) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL15033137 | 0.89 | DRD1 (0.60) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL3698679 | 0.85 | DRD1 (0.86) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL23975613 | 0.83 | DRD1 (0.66) | DRD1DRD5DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL10702384 | 0.83 | DRD1 (0.83) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL2607471 | 0.82 | DRD1 (0.62) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL29515933 | 0.80 | DRD1 (0.88) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL14340583 | 0.80 | DRD1 (0.88) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL24702127 | 0.79 | DRD1 (0.60) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL15088517 | 0.79 | HRH3 (0.61) | DRD1DRD5DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-2788086-B1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2788333-B1 | 1,2,4-TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA | BOEHRINGER INGELHEIM INT (DE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2013083741-A1 | 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083591-A1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | DRD1 3812/4885DRD5 3383/4885DRD2 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.